NLM Logo

Clinical Trials, Phase III as Topic MeSH Descriptor Data 2023


MeSH Heading
Clinical Trials, Phase III as Topic
Tree Number(s)
E05.318.372.250.250.220
N05.715.360.330.250.250.220
N06.850.520.450.250.250.220
Unique ID
D017326
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D017326
Annotation
for general design, methodology, economics, etc. of phase III clinical trials; a different heading CLINICAL TRIAL, PHASE III is used for reports of a specific phase III clinical trial
Scope Note
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Entry Term(s)
Clinical Trials, Phase 3 as Topic
Drug Evaluation, FDA Phase 3 as Topic
Drug Evaluation, FDA Phase III as Topic
Evaluation Studies, FDA Phase 3 as Topic
Evaluation Studies, FDA Phase III as Topic
Previous Indexing
Clinical Trials (1980-1992)
Public MeSH Note
2008; see CLINICAL TRIALS, PHASE III 1993-2007; for DRUG EVALUATION, FDA PHASE III see CLINICAL TRIALS 1980-1992; for EVALUATION STUDIES, FDA PHASE III see CLINICAL TRIALS 1982-1992
History Note
2008(1993)
Date Established
1993/01/01
Date of Entry
1992/05/13
Revision Date
2018/06/29
Clinical Trials, Phase III as Topic Preferred
Evaluation Studies, FDA Phase III as Topic Narrower
page delivered in 0.163s